GlassScriptPhysician profile
Ian A Harding
NPI 1790724227
$15,713.85
in general payments reported to CMS, 2019-2025
32 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $178 · 2021: $329 · 2022: $494 · 2023: $526 · 2024: $456 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $1,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,562.50 |
| Food and Beverage | $1,736.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $12,562.50 | 2025 | Rise, Creo |
| Pfizer INC. | $575.95 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $342.73 | 2021-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $337.66 | 2019-2025 | Bexsero |
| Merck Sharp & Dohme LLC | $320.73 | 2019-2025 | Vaxelis, Gardasil 9, M-M-R II |
| Corium, LLC | $247.17 | 2022-2025 | Azstarys |
| Sanofi Pasteur INC. | $198.63 | 2019-2025 | |
| Seqirus USA INC | $107.98 | 2021-2024 | Flucelvax, Flucelvax Quadrivalent |
| Alexion Pharmaceuticals, INC. | $97.43 | 2021-2025 | Strensiq |
| Sobi, INC | $96.16 | 2019-2023 | |
| Cranial Technologies, INC | $86.15 | 2023-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $78.84 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $66.07 | 2019-2020 | |
| Phadia US INC. | $65.51 | 2019-2024 | Immunocap |
| Hologic Sales and Service, LLC | $59.62 | 2023 | Aptima, Third Wave |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $51.64 | 2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $47.03 | 2022 | |
| Sanofi-Aventis U.S. LLC | $44.10 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $40.53 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.45 | 2020-2022 | |
| Shire North American Group INC | $39.26 | 2019 | |
| Kaleo, INC. | $30.90 | 2019-2024 | Auvi-Q |
| Kyowa Kirin, INC. | $22.37 | 2024 | Crysvita |
| Nestle Healthcare Nutrition INC. | $19.67 | 2021 | |
| Abbvie INC. | $19.02 | 2020 | |
| Aimmune Therapeutics, INC. | $18.92 | 2021 | |
| Mylan Pharmaceuticals INC. | $18.91 | 2019 | |
| Medtronic, INC. | $16.63 | 2025 | |
| Genzyme Corporation | $16.33 | 2025 | |
| Uswm, LLC | $16.00 | 2021 | |
| Tris Pharma INC | $15.17 | 2022 | |
| Genentech USA, INC. | $13.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Harding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.